191 related articles for article (PubMed ID: 17017952)
1. Anti-TNF-alpha antibody therapies in autoimmune diseases.
Chatzantoni K; Mouzaki A
Curr Top Med Chem; 2006; 6(16):1707-14. PubMed ID: 17017952
[TBL] [Abstract][Full Text] [Related]
2. Advances in the treatment of autoimmune diseases; cellular activity, type-1/type-2 cytokine secretion patterns and their modulation by therapeutic peptides.
Mouzaki A; Deraos S; Chatzantoni K
Curr Med Chem; 2005; 12(13):1537-50. PubMed ID: 15974986
[TBL] [Abstract][Full Text] [Related]
3. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions.
Sfikakis PP
Curr Dir Autoimmun; 2010; 11():180-210. PubMed ID: 20173395
[TBL] [Abstract][Full Text] [Related]
4. Incidence and nature of infectious disease in patients treated with anti-TNF agents.
Raychaudhuri SP; Nguyen CT; Raychaudhuri SK; Gershwin ME
Autoimmun Rev; 2009 Dec; 9(2):67-81. PubMed ID: 19716440
[TBL] [Abstract][Full Text] [Related]
5. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?
Feldmann M; Maini RN
Annu Rev Immunol; 2001; 19():163-96. PubMed ID: 11244034
[TBL] [Abstract][Full Text] [Related]
6. [Tumor necrosis factor alpha (TNF-α) in autoimmune diseases (AIDs): molecular biology and genetics].
Fragoso JM; Vargas Alarcón G; Jiménez Morales S; Reyes Hernández OD; Ramírez Bello J
Gac Med Mex; 2014; 150(4):334-44. PubMed ID: 25098219
[TBL] [Abstract][Full Text] [Related]
7. The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics.
Jang DI; Lee AH; Shin HY; Song HR; Park JH; Kang TB; Lee SR; Yang SH
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800290
[TBL] [Abstract][Full Text] [Related]
8. [TNF inhibitors: a new therapeutic perspective in chronic inflammatory diseases in rheumatology?].
Fenner H
Z Rheumatol; 1995; 54(3):158-64. PubMed ID: 7660686
[TBL] [Abstract][Full Text] [Related]
9. [Drug-induced liver injury with an autoimmune phenotype following anti-TNF Therapy - presentation of cases and review of literature].
Rösner S; Schad A; Kittner J; Rahman F; Wörns MA; Schuchmann M; Galle PR; Schattenberg JM
Z Gastroenterol; 2014 Jan; 52(1):58-63. PubMed ID: 24420801
[TBL] [Abstract][Full Text] [Related]
10. Biology of tumor necrosis factor-alpha- implications for psoriasis.
Schottelius AJ; Moldawer LL; Dinarello CA; Asadullah K; Sterry W; Edwards CK
Exp Dermatol; 2004 Apr; 13(4):193-222. PubMed ID: 15086336
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-alpha.
Edwards CK; Zhou T; Zhang J; Baker TJ; De M; Long RE; Borcherding DR; Bowlin TL; Bluethmann H; Mountz JD
J Immunol; 1996 Aug; 157(4):1758-72. PubMed ID: 8759766
[TBL] [Abstract][Full Text] [Related]
12. Potential target of infliximab in autoimmune and inflammatory diseases.
Atzeni F; Doria A; Carrabba M; Turiel M; Sarzi-Puttini P
Autoimmun Rev; 2007 Sep; 6(8):529-36. PubMed ID: 17854744
[TBL] [Abstract][Full Text] [Related]
13. Autoantibody production in anti-TNF-alpha-treated patients.
Alessandri C; Scrivo R; Spinelli FR; Ceccarelli F; Magrini L; Priori R; Valesini G
Ann N Y Acad Sci; 2007 Sep; 1110():319-29. PubMed ID: 17911447
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination.
Selmaj K; Raine CS; Cross AH
Ann Neurol; 1991 Nov; 30(5):694-700. PubMed ID: 1722388
[TBL] [Abstract][Full Text] [Related]
15. Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases.
Illei GG; Lipsky PE
Curr Opin Immunol; 2000 Dec; 12(6):712-8. PubMed ID: 11102777
[TBL] [Abstract][Full Text] [Related]
16. Autoantibodies in psoriatic patients treated with anti-TNF-α therapy.
Bardazzi F; Odorici G; Virdi A; Antonucci VA; Tengattini V; Patrizi A; Balestri R
J Dtsch Dermatol Ges; 2014 May; 12(5):401-6. PubMed ID: 24797746
[TBL] [Abstract][Full Text] [Related]
17. Anti-cytokine antibodies for rheumatic diseases.
Atzeni F; Sarzi-Puttini P
Curr Opin Investig Drugs; 2009 Nov; 10(11):1204-11. PubMed ID: 19876788
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and autoimmunity during anti-TNF therapy.
Atzeni F; Talotta R; Salaffi F; Cassinotti A; Varisco V; Battellino M; Ardizzone S; Pace F; Sarzi-Puttini P
Autoimmun Rev; 2013 May; 12(7):703-8. PubMed ID: 23207283
[TBL] [Abstract][Full Text] [Related]
19. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases.
Feldmann M; Maini RN
Nat Med; 2003 Oct; 9(10):1245-50. PubMed ID: 14520364
[No Abstract] [Full Text] [Related]
20. B lymphocytes contribute to autoimmune disease pathogenesis: current trends and clinical implications.
Tuscano JM; Harris GS; Tedder TF
Autoimmun Rev; 2003 Mar; 2(2):101-8. PubMed ID: 12848966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
